Business Description
Atossa Therapeutics Inc
NAICS : 325413
SIC : 2835
ISIN : US04962H5063
Description
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.93 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 42.2 | |||||
| 3-Year EPS without NRI Growth Rate | 49.5 | |||||
| 3-Year FCF Growth Rate | 45.5 | |||||
| 3-Year Book Growth Rate | 8.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -8.29 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.21 | |||||
| 9-Day RSI | 35.18 | |||||
| 14-Day RSI | 34.66 | |||||
| 6-1 Month Momentum % | 14.02 | |||||
| 12-1 Month Momentum % | 56.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.3 | |||||
| Quick Ratio | 13.3 | |||||
| Cash Ratio | 12.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -38.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -31.37 | |||||
| ROA % | -29.61 | |||||
| ROIC % | -485.66 | |||||
| ROC (Joel Greenblatt) % | -2319.23 | |||||
| ROCE % | -34.38 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.75 | |||||
| Price-to-Tangible-Book | 1.75 | |||||
| EV-to-EBIT | -1.73 | |||||
| EV-to-Forward-EBIT | -1.52 | |||||
| EV-to-EBITDA | -1.73 | |||||
| EV-to-FCF | -2.61 | |||||
| Price-to-Net-Current-Asset-Value | 1.81 | |||||
| Price-to-Net-Cash | 1.87 | |||||
| Earnings Yield (Greenblatt) % | -57.8 | |||||
| FCF Yield % | -15.1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ATOS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Atossa Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.22 | ||
| Beta | 1.49 | ||
| Volatility % | 93.27 | ||
| 14-Day RSI | 34.66 | ||
| 14-Day ATR ($) | 0.072787 | ||
| 20-Day SMA ($) | 1.151685 | ||
| 12-1 Month Momentum % | 56.45 | ||
| 52-Week Range ($) | 0.77 - 2.31 | ||
| Shares Outstanding (Mil) | 125.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Atossa Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Atossa Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Atossa Therapeutics Inc Frequently Asked Questions
What is Atossa Therapeutics Inc(ATOS)'s stock price today?
The current price of ATOS is $1.03. The 52 week high of ATOS is $2.31 and 52 week low is $0.77.
When is next earnings date of Atossa Therapeutics Inc(ATOS)?
The next earnings date of Atossa Therapeutics Inc(ATOS) is 2025-04-01 Est..
Does Atossa Therapeutics Inc(ATOS) pay dividends? If so, how much?
Atossa Therapeutics Inc(ATOS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers